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Summary The expression of p53 protein was immunohistochemically studied in formalin-fixed paraffin-
embedded biopsy specimens of 203 colorectal carcinomas by use of a monoclonal antibody specific for the p53
protein, PAbl8OL. p53 protein expression with its reactivity localised in nuclei was found in 121 (59.6%) of the
cancers. There was no correlation of pS3 immunoreactivity with histological classification, wall invasion,
lymphatic invasion, venous invasion, lymph node metastases, or peritoneal metastases. p53-positive cancers
were more frequently associated with liver metastasis than p53-negative ones. Patients with p53-positive
tumours had significantly poorer prognoses than those with p53-negative tumours. The 5 year survival rate
was 58.1% for patients with p53-positive tumours, and 76.3% for those with p53-negative tumours. In Dukes'
stage C tumours, an especially good correlation was found between p53 immunoreactivity and prognosis. In
addition, patients with p53-positive tumours had higher recurrence rates. The results indicate that p53
immunoreactivity may be a useful prognostic marker of colorectal cancers.
Germline or somatic inactivation of tumour suppressor genes
through point mutation or deletion plays an important role
in carcinogenesis. p53, one of these tumour suppressor genes,
is a cellular protein discovered through its association with
DNA virus antigen in murine cells (Lane & Crawford, 1979).
This protein may be localised in different cellular compart-
ments in normal and in transformed cells (Rotter et al.,
1983). The p53 protein in normal cells, or p53 of the wild
type, restrains cell growth, and probably acts as a tumour
suppressor (Fearon & Vogelstein, 1990; Lane & Benchimol,
1990, Levine, 1990). Crawford et al. (1981) reported that
many human tumour-derived cell lines show elevated levels
of p53 protein. In addition, the p53 protein in tumour-
derived cell is explained as the mutated forms ofp53 (Lane &
Benchimol, 1990). Also, a mutant p53 with an extended
half-life induces progression of growth-arrested, resting cells
to an active, cycling state, and causes immortalisation of
normal cells and their malignant transformation in coopera-
tion with H-ras oncogene (Mercer et al., 1982, Reich &
Levine, 1984; Parada, 1984). p53 expression has been
reported in a number of human tumours, including those of
the breast, lung and colorectum (Crawford, 1984; Cattoretti,
1988; Iggo, 1990). Several authors have recently shown the
relationship between p53 overexpression and prognosis in
breast cancer (Cattoretti et al., 1988; Iwaya et al., 1991). In
this study, we analysed 203 colorectal cancers immunohis-
tochemically, using the PAbl8O1 mouse anti-p53 MAb, and
found that p53 immunoreactivity is correlated with
clinicopathologic data and prognosis. Also, we report herein
the relationship between p53 overexpression and the DNA
ploidy pattern.
Materials and methods
We investigated the materials from 203 colorectal cancer
patients (112 colon, and 91 rectal cancer patients) who had
undergone resection of the malignancies in the Second
Department of Surgery, Kanazawa University. Carcinomas
were reviewed and graded by a single pathologist using
criteria recommended by the general rules of clinical and
pathological studies on cancer of colon, rectum and anus for
histological type, depth of tumour invasion, lymphatic
invasion and venous invasion (Japanese Research Society for
Cancer of Colon and Rectum, 1983). Seventy-eight of the
tumours were histologically diagnosed as well differentiated,
111 as moderately differentiated, five as poorly differentiated
adenocarcinomas, and the other nine as mucinous carcino-
mas. Liver metastases were found in 44 (21.7%), peritoneal
metastases in 16 (7.9%), and lymph node metastases in 98
(48.3%) of the patients. Twenty-five patients had stage A; 68,
stage B; 55, stage C, and 55, stage D cancers by the Dukes
classification.
The biopsy and resected specimens of the 203 lesions were
fixed in 10% formalin overnight and embedded in paraffin.
Thirty-nine surgically resected specimens were fixed by the
AMeX (acetone, methyl benzoate, and Xylene) method (Sato
et al., 1986) and embedded in paraffin. Their sections were
dewaxed, and the endogenous peroxidase activity was block-
ed by incubation of the sections in 1% hydrogen peroxidase
in methanol for 30 min. The hydrated sections were incu-
bated in a 1:5 dilution of normal goat serum at room
temperature for 15min to reduce non-specific staining, and
incubated with a 1:20 dilution of primary monoclonal anti-
body PAbl801 (NOVOCASTRA Labo., Newcastle Univer-
sity) at room temperature for 2 h. After washing with Tris
Buffer saline (TBS), the slides were incubated with a 1:30
dilution of biotinylated goat anti-mouse immunoglobulin G
(TAGO INC, Burlingame CA, USA) at room temperature
for 30 min, followed by incubation with a 1:100 dilution of
streptoavidin-biotin-peroxidase complex (DAKO Patts) at
room temperature for 30min. The peroxidase activity was
developed with 3-3'-diaminobenzidine tetrahydrochloride
(DAB). Finally, the slides were stained with methyl green for
10 min. Negative control studies were carried out in the
absence of the primary antiserum to p53. p53 staining was
considered positive when neoplastic cells were clearly stained
in the nucleus.
Thirty-micron-thick paraffin sections were deparaffinised
with xylene, and then dehydrated in ethanols. The specimens
were washed with distilled water and incubated in a 0.5%
pepsin solution (Sigma Chemical Co., St Louis, MO, USA)
at 37°C for 30 min. Nuclei were then filtered through a 37 g.m
nylon mesh, washed twice with RPMI 1640 (GIBCO, Grand
Island, NY, USA), and centrifuged. The remaining pellet was
incubated in Hanks' solution containing 0.2% EDTA and
0.01% ribonuclease (Sigma Chemical Co., St Louis, MO,
USA) at 37°C for 20 min, then centrifuged, resuspended in
1.0 ml of propidium iodide (50 jig ml-; Sigma Chemical Co.,
St Louis, MO, USA) in TBS, and incubated in the dark at
4°C for 1 h. About 20,000 cells were analysed with an EPICS
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Figure 1 Immunohistochemical staining of p53 using a monoclonal antibody PAbI801. Nuclear staining is positive in almost all
cancer cells.
C flow cytometer. A tumour with a single GO/1 was con-
sidered diploid, and diploid tumours were assigned a DNA
index of 1.00. An additional abnormal GI peak indicated the
presence of aneuploid.
Statistical analyses of data were performed by the chi-
square or Student's t-test. The outcomes from different
groups of patients were compared by the generalised Wil-
coxon test.
Results
There were 121 cancers (59.6%) having the evidence of p53
protein overexpression with the reaction localised in the
nuclei. Reaction-positive cells were distributed in almost all
the cancer cells, but never demonstrated in normal colorectal
mucosa (Figure 1). In 39 ofthe patients, p53 immunoreactivity
could be determined in both formalin-fixed paraffin-embedded
biopsy specimens and AMeX fixed paraffin-embedded resected
ones; and 35 (89.8%) of them had the same pattern of p53
immunoreactivity in both specimens. More precisely, 23 of
the patients had p53-positive tumours and 12, p53-negative
tumours in both resected and biopsy specimens, while the
other four (10.2%) differed in p53 immunoreactivity: three
had p53-negative biopsy specimens and p53-positive resected
specimens, and another, p53-positive biopsy specimens and
p53-negative resected specimens (Table I).
The relationship between p53 protein expression and clini-
copathological findings is shown in Table II. There was no
correlation between p53 protein expression and histological
Table I Correlation between p53 immunoreactivity of endoscopic
biopsy and that of resected specimens. There is a relatively good
correlation between two groups
Resected specimens Biopsied specimens (paraffin)
(AMeX) p53 (+) p53 (-)
p53 (+) 12 (30.8%) 1 (2.6%)
p53 (-) 3 (7.6%) 23 (59.0%)
classification, wall invasion, lymphatic invasion, venous
invasion, lymph node metastases, or peritoneal metastases.
The p53 protein-positive rate was 56.0% for 159 tumours
without liver metastasis, and 72.7% for 44 tumours with liver
Table II The relationship between p53 protein expression and
clinicopathological findings
No. of Cases
Viables cases p53 (+) (%)
Location
Colon 112 67 (59.8%) NS
Rectum 91 54 (59.3%)
Histological type
Well differentiated 78 46 (59.0%)
Moderately differentiated 111 70 (63.1%) NS
Poorly differentiated 5 3 (60.0%)
Mucinous 9 2 (22.2%)
Depth of tumour invasion
m, sm 8 4 (50.0%)
pm 22 13 (59.1%)
ss 106 63 (59.4%)
s 53 33 (62.3%) NS
si 14 8 (57.1%)
Lymphatic invasion
Negative 44 23 (52.3%) NS Positive 159 98 (61.6%)
Venous invasion
Negative 118 65 (55.1%) NS Positive 85 56 (65.9%)
Lymph node metastasis
Negative 105 61 (58.1%) NS
Positive 98 60 (61.2%)
Hepatic metastasis
Negative 159 89 (56.0%) P< 05 Positive 44 32 (72.7%)
Peritoneal metastasis
Negative 187 110 (58.8%) NS
Positive 16 11 (68.8%)
m, mucosa; sm, submucosa; pm, propia muscle; ss, subserosa, s,
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metastasis. There was a significant difference in the rate of
liver metastasis between these two groups (P<0.05). By
Dukes' staging, the p53 protein-positive rate was 68% for
Dukes' stage A, 57.4% for Dukes' stage B, 47.3% for Dukes'
stage C and 70.9% for Dukes' stage D tumours (Table III).
There was no significant correlation between Dukes' stages
and p53 immunoreactivity.
Figure 2 depicts the Kaplan-Meier curves for the survival
of these two groups of patients. The 5-year survival rate was
76.3% for 82 patients with p53-negative tumours. However,
the prognosis was poor in 121 patients with p53-positive
tumours, and the 5-year survival rate was 58.1% for this
group. The difference between these two groups was statis-
tically significant (P<0.05). Among the patients with Dukes'
stage A and B tumours, no difference was found in survival
between the patients with p53-positive and those with p53-
negative tumours, with the 5-year survival rates of 96.5%
and 95.5%. Furthermore, there was no significant difference
between the survival rates and the patterns of p53 immuno-
reactivity in patients with Dukes' stage D tumours. Among
the 55 patients with Dukes' stage C tumours, however, those
with p53-negative tumours survived significantly longer than
those with p53-positive tumours (P<0.05) (Figure 3). The
5-year survival rates were 59.2% for 26 patients with p53-
positive tumours, and 88.9% for those with p53-negative
tumours. In 148 patients who underwent curative resection
we examined the relationship between recurrence rate and
p53 immunoreactivity. The patients with p53-negative
tumours gave a recurrence rate of 7.6%, while those with
p53-positive tumours recorded a recurrence rate of 18.3% the
difference between the two groups was statistically significant
(P<0.05).
In flow cytometric analysis, DNA diploidy (diploid) was
detected in 52 (40.3%) of 129 patients, and 77 (59.7%) of the
patients had tumours with DNA aneuploidy containing an
abnormal DNA stemline (aneuploid). Forty-nine patients
with p53-negative tumours consisted of 21 with diploid and
28 with aneuploid tumours, while 80 patients with p53-
positive tumours were composed of 31 with diploid and 49
with aneuploid tumours. There was no correlation between
the p53 immunoreactivity and the DNA ploidy pattern
(Table IV).
Table III p53 immunoreactivity patterns and Dukes' stages. There
is no correlation between p53 immunoreactivity patterns and Dukes'
stages
Dukes' stage No. of cases pS3 (+) Cases (%)
A 25 17 (68.0%)
B 68 39 (57.4%)
C 55 26 (47.3%)
D 55 39 (70.9%)
NS
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Figure 2 Survival curves for all patients with colorectal car-
cinoma, classed by p53 immunoreactivity. Patients with p53-
positive tumour run significantly poorer prognoses than those
with p53-negative tumours.
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Figure 3 Survival curves for patients with Dukes' stage C
tumour. Five-year survival rates are 88.9% for 29 patients with
p53-negative tumour, and 59.2% for patients with p53-positive
tumour: the difference between the two groups of patients is
statistically significant.
Table IV Correlation between p53 immunoreactivity and DNA
ploidy patterns
DNA ploidy pattern
p53 immunoreactivity Diploid Aneuploid
(-) 21 (42.9%) 28 (57.1%)
(+) 31 (38.8%) 49 (61.3%)
NS
Discussion
We analysed the p53 protein expression immunohistochemic-
ally in colorectal cancers, using the PAbl801 mouse anti-p53
MAb. PAbl801 is a monoclonal antibody to human p53
protein that recognises a denaturation-resistant epitope
between the amino acids 32 and 79 (Banks et al., 1986).
PAbl801 is reactive on both the wild type and mutant forms
of p53. However, the level of wild type p53 is low, with a
short half-life (Oren et al., 1981; Reich et al., 1983). On the
other hand, the level of mutant p53 is 100-fold higher than
that of the wild type p53, with a long half-life. In our study
p53 immunoreactivity with PAbl801 was localised in the
nuclei of cancer cells, and normal epithelia adjacent to
cancers were completely negative for p53. Consequently, we
have come to think that PAbl801 detects only the mutant
p53 protein in formalin-fixed paraffin-embedded sections.
We compared the p53 immunoreactivity of formalin-fixed
biopsy specimens with that of AMeX-fixed resected speci-
mens. Thirty-five (89.8%) of the 39 suitably studied patients
proved to have the same p53 immunoreactivity pattern in
both specimens. p53 immunoreactivity was found in 121
(59.6%) of the 203 lesions, and was mainly nuclear, irrespec-
tive of fixation. Several investigators have reported the pre-
sence of p53 reactivity in colorectal cancers. Kawasaki et al.
(1992), using microwave-fixed, paraffin-embedded sections,
reported that nuclear p53 was detected in 51 (60.7%) of 84
colorectal cancers. We therefore concluded that it would be
possible by use of PAbl801 to analyse the p53 immunore-
activity in formalin-fixed biopsy specimens preoperatively.
Recent studies have shown a close correlation between p53
immunoreactivity and prognosis of several malignant tumours.
Cattoretti et al. (1988) demonstrated that p53 expression is
associated with presence of the oestrogen receptor, the
growth factor receptor, and the proliferation-associated
antigen Ki-67 in breast cancer. Iwaya et al. (1991) reported
that p53 protein immunoreactivity is a clinically useful indi-
cator of breast cancer aggressiveness. We previously reported
that immunoreactivity of p53 is an independent prognostic
indicator of colorectal cancer (Yamaguchi, 1992). In addi-
tion, Kern et al. (1989) reported that deletion of 17p and that
of 18q were significantly associated with distant metastasis
and prognosis. Knowing the malignant potential preopera-
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tively is important in choosing an adequate therapeutic
method and in prognosis. We have therefore studied p53
immunoreactivity in endoscopic biopsies of colorectal cancer.
There was no significant correlation between p53 immuno-
reactivity and histological classification, wall invasion, lym-
phatic invasion, venous invasion, lymph node metastases, or
peritoneal metastases. Previous immunohistochemical studies
of p53 described no significant correlation between p53 ex-
pression and site, differentiation, or Dukes' stage (Purdie,
1991). In our study, however, the patients with p53-positive
tumours had a higher rate of liver metastases. In addition,
p53 immunoreactivity showed a close inverse correlation with
prognosis. By Dukes' staging, the 5-year survival rate of
patients with Dukes' stage A and B tumour was over 90%,
while the prognosis was very poor in patients with Dukes'
stage D. Therefore, there was no significant correlation
between p53 immunoreactivity and prognosis in Dukes' A, B
and D cases. However among the patients with Dukes' stage
C cancers, survival was significantly shorter when the tumour
was p53-positive. Furthermore, the patients with p53-positive
tumours had a greater relative risk of recurrence.
In general, aneuploid tumours are associated with poor
prognosis (Wolley et al., 1982; Armitage et al., 1985). Here,
however, we show no correlation between p53 immunoreac-
tivity and DNA ploidy an observation similar to that of
Scott et al. (1991). However, we previously reported that the
growth fraction of p53-positive tumours is significantly
higher than that ofp53-negative tumours (Yamaguchi, 1992).
Also, we argued that the detection of growth fraction by use
of a monoclonal antibody against DNA polymerase a
enables the measurement of proliferative activity, and that
the growth fraction of colorectal cancers is a useful prognos-
tic indicator. We suggested therefore that the poor survival
of patients with p53-positive tumours might be associated
with a high cell proliferative activity. From the findings, it
may be concluded that the p53 immunoreactivity detected by
use of PAbl801 is a useful prognostic indicator of colorectal
cancers, and that it would permit the preoperative analysis of
biopsy specimens.
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